Guidance Issuing Office
Office of Regulatory Affairs
Compliance Policy Guide Sec. 230.120- Human Blood and Blood Products As Drugs is obsolete and was withdrawn on 1/30/2020.
Issued 6/17/74
Revised 10/1/80
Withdrawn: 1/30/2020
Submit Comments
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 – Specific Electronic Submissions Intended For FDA’s Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.
-
Content current as of:
01/30/2020
-
Regulated Product(s)
Topic(s)
